IL6 and metabolic dysfunction-associated steatotic liver disease: In MASLD patients, a reduction in Adlercreutzia equolifaciens was observed, and in vivo and in vitro models confirmed its anti-inflammatory effects via reduced interleukin-6 (IL-6) expression [32].